Overcoming challenges in CAR T-cell therapy for multiple myeloma

Mohamad Mohty, MD, PhD, Saint-Antoine Hospital, Paris, France, expresses optimism regarding current immunotherapeutic options in multiple myeloma (MM), such as CAR T-cells and bispecific antibodies. Prof. Mohty highlights the approved CAR-T therapies, idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel), with the primary challenge being enhancing long-term progression-free survival (PFS) in the relapsed/refractory (R/R) setting. When manufacturing CAR T-cells, factors such as the target T-cell population, construct design, tumor antigen, and the potential of dual targeting should be considered to increase the likelihood of positive outcomes. Despite the challenges, CAR-T therapy offers the advantage of a single infusion, reducing the treatment burden for patients. This interview took place at the EBMT-EHA 6th European CAR T-cell Meeting in Valencia, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.